Commercial Simon us our morning. Dr. Horn, Officer; Pat Great. Officer. our Pamela Medical Thank thank are Officer; today Harford, you, With our me for and and Financial everybody Chief this Paul Chief you Chief joining Stephenson,
in commitment hardworking visit been of pandemic. even I III the on my to our times. these track the odevixibat on report heartfelt last programs face Phase each I our the challenges, extraordinary elobixibat here Executing who Despite in before feat, for an our is to dive upon we're the team to moving no each Phase give COVID-XX has small our and So, forward the tremendous programs Albireo, achieved of shown keeping programs, and in NASH patient, at pleased study. wanted have II thanks best of our study strategy PFIC into of last and update that global
patients first the The regulatory odevixibat atresia the U.S. to enrolled European with and have III we've pivotal biliary been syndrome. agencies of study, design in on program agreement Phase Alagille third in the odevixibat and a come
topline and We upon our for for continue prepare plans execute as to data. build we commercialization
a With the since key sheet a team's as data our quality strong on, rich have beginning with we and position of we optimistic XXXX, because of deliver about second our milestones possible our Following feel half topline our supporting balance our announcements, to is execution. company. which focus of activities
of at many Now place. first were for we our In programs. PFIC, when our the or were Familial enrolled odevixibat Phase each look fortunate put have trial a fully for Cholestasis III restrictions in Progressive closer COVID-XX of Intrahepatic to
to aligned expect with fiercely At last patients we've review voucher important visit include pleased the anticipate lost no committed patients, launch will the second Albireo, weeks, to that I'm dedicated results programs. of data achieved now a XXXX. two due out follow-up supporting have issuance and COVID-XX. to planned approval, to of half continue and the to we mid-XXXX We priority our in of in and be We coming patient patients, enrolled a guidance. XX topline really XX commercial to
and EAP, Europe. access PEDFIC now to all announced eligible odevixibat Access we an to the X Through open-label we Canada, the EAP, U.S., patients for in increase for or trial of First, our with Program, and launch Expanded PFIC launch Australia, our the other these hope countries and to until possible extent to PFIC working first with patients regulators and for greatest we're countries to access the program worldwide. continue We're offer closely families in is in to pleased odevixibat provide available. local commercially hope
genetics Second, testing.
We for and other patients U.S. demonstrate for in toward commitment supporters industry syndrome program genetic partners. provide Both PFIC to to a in are in planned but the are more testing Alagille strong free who be helping happy programs to commercialization, patients importantly, a our movement with of support need.
outcomes Key earlier observer-reported that including into on the Opinion quarter and We has study to endpoint. this X implementation clinical the PEDFIC incorporate outcome provide and hosted and input PEDFIC Leader assessments, our to X. X design FDA's patient-reported are We pruritus designed event been in primary carefully background confident a of
tools for PFIC. clinical FDA, the who the for for on design the through have the that the we expert we Our consultation provided an were the caregivers, and of in assessments patients submission study, development content practices precision measurement items, feedback including the draft provide interview outcome of to clinicians process response designed with done, considerable tools, scales. using it and requires and quality measurements Based odevixibat work NDA validity the will FDA best believe
We've commercializations active front. high on that been Now, gear. for in plans are very
supply with way, chain for executing FDA partners is from in is on with EU, place Stability well. program U.S. manufacturing well the XXXX. are registration input support packaging and as under our plan the and and for CMC Our our the in fall received the we and testing partner shape plants of selected patient the are taking batches
with As our in of favorable our more profile. to say much for PFIC. once-a-day patients need shape, convinced offering and to clear an get have more are we that We'll begin than treatment the safety options on we drug exposure minimal today, as closer to this commercialization systemic launch. plans believe a and we better opportunity for with orphan dosing we're ever, a market With take oral exclusivity, designation well-positioned
first treatments active biliary placebo-controlled have study intervention which We in the Phase with and pediatric in in quarter. in atresia, our development States delighted odevixibat the conducted United sites with liver the and of children atresia. guidance prospective the odevixibat with is transplant. for the liver liver XH program a no our There despite approved in infants treatment. last of efficacy for is on III compared a to liver alive randomized, randomized patient initiated in indication patients the double-blind, disease odevixibat evaluate our of study safety atresia, XXXX ever we're This enrollment. rare trial trial approximately pivotal and common to second after the XXX Moving a biliary the pharmacological Clinical indication. a disease have study placebo is atresia, two designed procedure. BOLD of cholestatic the challenges proportion And fulfilled pediatric biliary is years to and undergone cholestatic expanding most COVID-XX. endpoint the BOLD biliary undergone largest who who are transplant of primary are for are Kasai have currently not The patients leading to
orphan our syndrome, come received out III for in We've and where of in the authorities drug agreement design year. on have study to for pivotal third the both for and trial have single protocol U.S. drug received we EU. EU approval and in plan the We designation regulatory designations a orphan by the Rounding the program is necessary initiate a U.S. regions. to the atresia of with biliary Phase Alagille our odevixibat end
of Let are general NASH with there massive in mortality risk people me approximately the with approved treatments. XX It U.S. tenfold million now with compared This market presents move to estimated greater to our a a opportunity population. pipeline liver-related is products. the no
efficacy is the it of our thesis have ongoing While struggling non-systemic are efficacy safety. and and a elobixibat the products two safety, balance have NAFLD. our trials with in and of of many program, balance Phase in II drug In could current NASH right development that we the
PEDFIC visit are coming study, expecting weeks, guidance. topline For patient, last read X Phase study. our III out This last ahead the study U.S. fulfilling data the and completed the elobixibat of will mid-XXXX five-milligram we in odevixibat
XX the have lost will COVID patients primarily to as follow-up, XX on to randomized four XX. were We due of data
being at or IBAT We're Japan, There a inhibitors and our second study. this year. both early partner, endpoints in anticipating we our no of end topline studies in Pharma of year to NASH/NAFLD. conducted in EA XX-milligram data biopsy trial the as eagerly designed are important provide For next the data are this reiterate through these guidance proof-of-concept anticipate elobixibat
important of trends XX% fat reduction of tolerability, and liver studies, enzymes of manageable for good in is of endpoint in both primary as MRI-PDFF meaning XX% positive lowering positive disease factors change combination potentially enzymes. in looking parameters, this the LDL, such stabilization and with endpoints with at liver reduction diarrhea. and in by health, and improvement With secondary least trends LDLC For liver fat to measured rate GI cardiovascular liver are we a of liver
assets. a further seek is both of to this for one partnership from emerging our accumulate and potentially elobixibat intent studies data preclinical development Our and for
Phase one with III the our validating in We biliary truly before to data we data are atresia; year progressing III our in by programs. the of with ahead early for us topline trial Alagille forward Phase believe programs coming be BOLD by odevixibat in in each very syndrome odevixibat on end weeks; our by continue with third the our anticipated our as are very and best-in-class the with; our year; well our increased II half we summary, focus second elobixibat the product Japanese year, initiated of next of of the and Phase look trial, year anticipated building patients partners NASH two the special So, to assets something data a pipeline momentum which end. late-stage PFIC and data excited from to as will starting or trials in opportunities of enroll in
approval including and biliary Additional review and atresia completion launch year. the milestones for in and commercial odevixibat PFIC priority trial for study issuance XXXX, voucher next a of the of initiation anticipated into a
meaningful We and a potential opportunity We're of appreciate your on Albireo. are that ahead period lies the of cusp and and for exciting truly really support. very certain the
my it's to pleasure with for the Simon turn Simon? update. now financial that, So, call a to over
